Pharma-Bio Serv, Inc. (PBSV) stock
PBSVOTCServices-Management Consulting ServicesFiscal year ends October 31
$0.48+0.08 (+20.00%)
Close on Oct 19, 2026Market cap $11.00MP/E 48.0Yield –
Pharma-Bio Serv operating margin
Operating margin is operating income as a percentage of revenue.
Pharma-Bio Serv's operating margin for the twelve months ending Jul 31, 2026 was -1.6%. For fiscal 2025 it was -7.1%, against -13.5% the year before. The highest annual figure on record is 19.6% in fiscal 2012.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | -7.1% | +6.5 |
| FY2024 | Oct 31, 2024 | -13.5% | −20.1 |
| FY2023 | Oct 31, 2023 | 6.6% | +0.5 |
| FY2022 | Oct 31, 2022 | 6.1% | +25.2 |
| FY2021 | Oct 31, 2021 | -19.2% | −29.5 |
| FY2020 | Oct 31, 2020 | 10.3% | +1.6 |
| FY2019 | Oct 31, 2019 | 8.7% | +15.8 |
| FY2018 | Oct 31, 2018 | -7.1% | −1.2 |
| FY2017 | Oct 31, 2017 | -5.8% | −5.4 |
| FY2016 | Oct 31, 2016 | -0.5% | −8.1 |
| FY2015 | Oct 31, 2015 | 7.6% | −2.8 |
| FY2014 | Oct 31, 2014 | 10.4% | −8.0 |
| FY2013 | Oct 31, 2013 | 18.4% | −1.3 |
| FY2012 | Oct 31, 2012 | 19.6% | +2.3 |
| FY2011 | Oct 31, 2011 | 17.3% | +11.9 |
| FY2010 | Oct 31, 2010 | 5.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | -3.1% | +12.9 |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | 5.4% | +9.4 |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | -4.1% | −0.4 |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | -6.2% | +0.4 |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | -16.0% | −0.2 |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | -4.1% | +9.1 |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | -3.7% | +14.7 |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | -6.6% | −5.2 |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | -15.8% | −25.8 |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | -13.2% | −21.5 |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | -18.4% | −26.2 |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | -1.4% | −8.3 |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | 10.1% | +95.8 |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | 8.3% | +1.1 |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | 7.8% | +2.5 |
| Q1 FY2022CQ4 2021 | Jul 31, 2022 | 6.8% | −0.3 |
| Q4 FY2021CQ3 2021 | Oct 31, 2021 | -85.7% | −88.7 |
| Q3 FY2021CQ2 2021 | Jul 31, 2021 | 7.2% | −5.8 |
| Q2 FY2021CQ1 2021 | Apr 30, 2021 | 5.3% | −7.5 |
| Q1 FY2021CQ4 2020 | Jan 31, 2021 | 7.1% | −4.5 |
| Q4 FY2020CQ3 2020 | Oct 31, 2020 | 3.0% | −5.8 |
| Q3 FY2020CQ2 2020 | Jul 31, 2020 | 13.0% | +5.7 |
| Q2 FY2020CQ1 2020 | Apr 30, 2020 | 12.8% | +3.5 |
| Q1 FY2020CQ4 2019 | Jan 31, 2020 | 11.6% | +1.3 |
| Q4 FY2019CQ3 2019 | Oct 31, 2019 | 8.8% | +0.1 |
| Q3 FY2019CQ2 2019 | Jul 31, 2019 | 7.3% | −8.3 |
| Q2 FY2019CQ1 2019 | Apr 30, 2019 | 9.3% | +9.5 |
| Q1 FY2019CQ4 2018 | Jan 31, 2019 | 10.3% | +76.7 |
| Q4 FY2018CQ3 2018 | Oct 31, 2018 | 8.8% | −0.5 |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | 15.6% | +20.5 |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | -0.2% | +8.0 |
| Q1 FY2018CQ4 2017 | Jan 31, 2018 | -66.3% | −56.9 |
| Q4 FY2017CQ3 2017 | Oct 31, 2017 | 9.3% | +19.0 |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | -4.9% | −2.4 |
| Q2 FY2017CQ1 2017 | Apr 30, 2017 | -8.3% | – |
| Q1 FY2017CQ4 2016 | Jan 31, 2017 | -9.5% | – |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | -9.7% | – |
| Q3 FY2016CQ2 2016 | Jul 31, 2016 | -2.5% | – |
See a number that looks wrong?